

*2019 KOPANA 18<sup>th</sup> Spring Seminar*  
*March 15-16, 2019, National Harbor, Maryland*

# Digital pathology and pathology informatics

Kyoungbun Lee, MD

Department of Pathology, Seoul National University Hospital

# Disclosure

- I have no conflict of interest



# Outline

- **Introduction of digital pathology**
- **Digital pathology for primary diagnosis**
  - Component of digital pathology system for primary diagnosis
  - Digital pathology workflow, SNUH
  - Issues in implementation of digital pathology system
- **Digital pathology for research**
  - Computational pathology : quantification, discrimination, prediction
  - Reconstruction
- **New technique for digital pathology**
  - Slide-free non-destructive pathology

# What is digital pathology?

➤ *Wikipedia* [[https://en.wikipedia.org/wiki/Digital\\_pathology](https://en.wikipedia.org/wiki/Digital_pathology)]

image-based information environment which is enabled by **computer technology** that allows for the management of information generated from a **digital slide**. Digital pathology is enabled in part by **virtual microscopy**, which is the practice of **converting glass slides into digital slides** that can be viewed, managed, shared and analyzed **on a computer monitor**. With the advent of Whole-Slide Imaging, the field of digital pathology has exploded and is currently regarded as one of the most promising avenues of diagnostic medicine in order to achieve even better, faster and cheaper diagnosis, prognosis and prediction of cancer and other important disease



# What can we do with digital pathology?

## ➤ What can we do with glass slide?

Education



Fig. 1. Computer laboratory for practical class using virtual microscopes.




Fig. 2. Screenshot of the virtual microscope. The ImageScope viewer shows a histopathologic lesion of the thumbnail at the right upper corner and the magnifier at the corner.






Figure 3: Whole slide images help create a "virtual multihed microscope" that supports interactive education (Image courtesy of BioImagene)

Research & bioindustry




Prognosis factor  
 Classification  
 Biomarker development  
 Toxicology  
 Drug development  
 : semi-quantitative grading  
 consensus meeting



Segmentation, quantification, computation, prediction



Primary diagnosis



Teleconference & -consult

# Outline

- Introduction of digital pathology
- **Digital pathology for primary diagnosis**
  - Component of digital pathology system for primary diagnosis
  - Digital pathology workflow, SNUH
  - Issues in implementation of digital pathology system
- **Digital pathology for research**
  - Computational pathology : quantification, discrimination, prediction
  - Reconstruction
- **New technique for digital pathology**
  - Slide-free non-destructive pathology

# Regulation of whole slide image for primary diagnosis

- US

Philips IntelliSite Pathology Solutions for primary pathology diagnosis

: 2000 surgical pathology cases (15,925 readings) : optical interpretation rate difference of 0.4% with a 95% confidence interval (-0.3-1.0) indicating noninferiority for digital versus optical reads

*Contains Nonbinding Recommendations*

## Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices

### Guidance for Industry and Food and Drug Administration Staff

Document issued on: April 20, 2016

The draft of this document was issued on February 25, 2015

For questions about this document, contact the Division of Molecular Genetics and Pathology at 301-796-6179 and Nicholas Anderson at 301-796-4310 or [nicholas.anderson@fda.hhs.gov](mailto:nicholas.anderson@fda.hhs.gov) or Aldo Badano at 301-796-2534 or [aldo.badano@fda.hhs.gov](mailto:aldo.badano@fda.hhs.gov).



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health

Office of *In Vitro* Diagnostics and Radiological Health  
Division of Molecular Genetics and Pathology  
Molecular Pathology and Cytology Branch

Stony Brook University

FDA News Release

### FDA allows marketing of first whole slide imaging system for digital pathology

SHARE TWEET LINKEDIN PIN IT EMAIL PRINT

For Immediate Release April 12, 2017

**Release**

The U.S. Food and Drug Administration today permitted marketing of the Philips IntelliSite Pathology Solution (PIPS), the first whole slide imaging (WSI) system that allows for review and interpretation of digital surgical pathology slides prepared from biopsied tissue. This is the first time the FDA has permitted the marketing of a WSI system for these purposes.

## Korea's Drug Ministry approves Philips digital pathology solution

By Sohn Ji-young

Published : Jul 10, 2018 - 16:08

Updated : Jul 10, 2018 - 16:08



Philips Korea announced Tuesday that South Korea's Ministry of Food and Drug Safety has approved its digital pathology solution, the Philips IntelliSite Pathology Solution, for diagnostic use in the country.

Pathologists in Korea can now use the digital pathology technology from Philips to assess and diagnose clinical histology cases digitally, instead of with a microscope, with the aim to enhance laboratory efficiency and quality, the firm said.

# Fully digitalized pathology lab.


2018, 8.17, University Medical Center Utrecht, Netherland, Amsterdam



*> 1,000 beds, > 10,000 employees  
20,000 /yr histopathology requests  
156,000 slides/yr  
15 pathologists, 10 residents*

*→ 6 scanner running*

2018.8.16, Linköping University Hospital, Linköping, Sweden



*30,000/yr histopathology requests  
180,000 slides/yr*

*20 pathologists*

*→ 27 digital work stations  
> 1,000,000 slides 440TB  
Start in 2010, full digital in 2017*





# Components of digital pathology

- Slide scanner : image acquisition
- Image management : data, messages, integration in LIS
- Viewer software and image storage system
- Image evaluation and analysis system
- Hardware of users : user workstation and viewing monitor



# Implementation of digital pathology & workflow, SNUH

# Change of pathology workflow



Digital pathology system

Laboratory (hospital) information system

***1<sup>st</sup> step : Traditional paper-based work-flow → paper-less workflow***

# Pathology PACS and HIS system: SNUH



Digital Gross Photography system



Sequencer PCR




FISH/IF/EM images



Slide scanner


HIS system, upgrade 2016




Order  
Patient information  
Paper-less pathology report  
Lab work-flow management  
Slide tracking system

Pathology image server  
(HUPAX, 2009, SNUH&Humintec)

Hospital Information System






Pathology PACS



Template




| Item                                | Value   | Unit | Normal Range | Item  | Value            | Unit | Normal Range |
|-------------------------------------|---|------|--------------|---|------------------|------|--------------|
| Intimal arteritis                   | absent  |      |              | Intimal arteritis absent (40)                   |                  |      |              |
| Interstitial inflammation           | mild  |      |              | Interstitial inflammation mild (5)              |                  |      |              |
| Allograft glomerulitis              | absent  |      |              | Allograft glomerulitis absent (6)               |                  |      |              |
| Chronic lesion scoring              |   |      |              | Chronic lesion scoring                          |                  |      |              |
| - Interstitial fibrosis             | mild  | 0-4  | 0-3          | - Interstitial fibrosis mild (10)               |                  |      |              |
| - Tubular atrophy                   | mild  | 0-4  | 0-3          | - Tubular atrophy mild (11)                     |                  |      |              |
| - Allograft glomerulopathy          | absent  | 0-3  | 0-2          | - Allograft glomerulopathy absent (12)          |                  |      |              |
| - Mesangial matrix increase         | absent  | 0-2  | 0-2          | - Mesangial matrix increase absent (13)         |                  |      |              |
| - Vascular fibromuscular thickening | absent  | 0-2  | 0-2          | - Vascular fibromuscular thickening absent (14) |                  |      |              |
| - Arteriole hyaline thickening      | absent  | 0-2  | 0-2          | - Arteriole hyaline thickening absent (15)      |                  |      |              |
| Peritubular capillaritis            | absent  | 0-3  | 0-3          | Peritubular capillaritis absent (16)            |                  |      |              |
| Glomerulus                          |   |      |              | Glomerulus                                      |                  |      |              |
| - Number of Glomeruli               | 35  |      |              | - Number of Glomeruli                           | 35               |      |              |
| - Global sclerosis                  | 0   | 0-3  | 0-2          | - Global sclerosis 0 (18.2%)                    |                  |      |              |
| - Segmental sclerosis               | 0   | 0-3  | 0-2          | - Segmental sclerosis 0 (0%)                    |                  |      |              |
| - Crescent                          | 0   | 0-3  | 0-2          | - Crescent 0 (0%)                               |                  |      |              |
| - Fibrocellular                     |   |      |              | - Fibrocellular                                 |                  |      |              |
| - Eosinophilic                      |   |      |              | - Eosinophilic                                  |                  |      |              |
| - Other                             |   |      |              | - Other   |                  |      |              |
| - Cellularity                       | mildly increased                              |      |              | - Cellularity                                   | mildly increased |      |              |
| - Involving                         | mesangial cells                               |      |              | - Involving                                     | mesangial cells  |      |              |
| - Other findings                    | absent  |      |              | - Other findings                                | absent           |      |              |
| - Interstitium                      |   |      |              | - Interstitium                                  |                  |      |              |
| - Blood vessels                     |   |      |              | - Blood vessels                                 |                  |      |              |
| - Others                            |   |      |              | - Others  |                  |      |              |
| Other findings                      | absent  |      |              | Other findings absent                           |                  |      |              |
| DIAGNOSIS                           | Kidney, allograft, post-transplantation 6 yrs |      |              |   |                  |      |              |
|                                     | 1. Borderline change (Banff 1B, 1C)           |      |              |   |                  |      |              |
|                                     | 2. Borderline change (Banff 1C)               |      |              |   |                  |      |              |

# HIS: main report



1. Order ancillary test
2. QA & QC
3. Statistics

# HIS: Frozen report



등록번호: [redacted]  
 수술일자: [redacted]  
 수술명: Salpingo-oophorectomy ( left / laparotomy )  
 임상진단: Ovarian cyst

입력된 채취부위 리스트

| 순번 | 채취부위                    | 상태   | 인계자 | 비고 |
|----|-------------------------|------|-----|----|
| 1  | LSO (Lt salpinx ovary ) | 관독완료 | 박 희 |    |
| 1  | LSO (Lt salpinx ovary ) | 관독완료 | 박 희 |    |

블럭생성일자: 2017-06-26 ~ 2017-06-26

블럭번호: [redacted]

블럭 리스트

| 동결번호        | 재취순번 | 블럭번호                      | 채취부위 | 블럭상태 | 크기1 | 크기2 | 크기3      | 진단 | 변환 |
|-------------|------|---------------------------|------|------|-----|-----|----------|----|----|
| FR170003313 | 1    | Fro 1 Sentinel node1 (Lt) |      | 관독완료 | 1.5 | 1.2 | No tumor | 변환 |    |
| FR170003313 | 2    | Fro 2 Sentinel node2 (Lt) |      | 관독완료 | 1.5 | 1.2 | No tumor | 변환 |    |
| FR170003313 | 3    | Fro 3 Lt. Non-sentinel #1 |      | 관독완료 | 1.2 | 1.0 | No tumor | 변환 |    |

동결결론 결과입력

구분: Main (1) 가관독



Frozen #1 Specimen received is 1.5 x 1.2 cm sized soft tissue.  
 Diagnosis: Sentinel node1 (Lt) : No tumor (이경분)

Frozen #2 Specimen received is 1.5 x 1.2 cm sized soft tissue.  
 Diagnosis: Sentinel node2 (Lt) : No tumor (이경분)

Frozen #3 Specimen received is 1.2 x 1.0 cm sized soft tissue.  
 Diagnosis: Lt. Non-sentinel #1 : No tumor (이경분)

# HIS: Automatic text loading

## 1. Cytology > Heading, screening result



## 2. Immunohistochemistry / special study > antibody item

병리검사번호 : S 17-0033968 (16)

검사결과:

- Cytokeratin (Pan CK) :
- Vimentin :
- ERG :
- CD31 :
- CD34 :

| 생검명 | 개수 | 크기1 | 크기2 | 크기3 | 부피 | 비고사항 | 슬라이드키 |
|-----|----|-----|-----|-----|----|------|-------|
| 1 E | 1  |     |     |     |    |      |       |
| 2 E | 2  |     |     |     |    |      |       |
| 3 E | 1  |     |     |     |    |      |       |
| 4 E | 1  |     |     |     |    |      |       |

**결과문 변환 내용**      **결과문 미리보기**

임상진단 : 받은 조직은 총 4 부분임.  
1. 포르말린에 고정된 매우 작은 생검조직임. 개수 : 1개    전부포매함.  
2. 포르말린에 고정된 매우 작은 생검조직임. 개수 : 2개    전부포매함.  
3. 포르말린에 고정된 매우 작은 생검조직임. 개수 : 1개    전부포매함.  
4. 포르말린에 고정된 매우 작은 생검조직임. 개수 : 1개    전부포매함.

MICRO (2 HE)  
DIAGNOSIS :

1. 채취부위 : #1 AV 40cm  
#2 AV 35cm  
#3 AV 30cm  
#4 AV 20cm  
2. 수 술 명 : Bx  
3. 임상진단 : #1 granular mucosal change  
#2-4 erosion & ulcer  
4. 수술소견 및 기타 :  
5. 오더비고 :

**관련 검사결과**

2017-06-27 : Sigmoidoscopy(병동)(소독)  
AV 40cm 상방에 easy touch bleeding을 동반하는 granular mucosal change가 관찰되어 Bx(#1) 시행함.  
AV 35cm, 30cm 상방에 luminal narrowing과 easy touch bleeding을 동반하는 diffuse mucosal erosion이 관찰되어 Bx(#2, #3) 시행함.  
AV 20cm 상방에 mucosal edema 및 several small ulceration이 관찰되어 Bx(#4) 시행함.

#1-#3 Bx 후 significant bleeding이 발생하였으나 들로 씻으며 관찰시 bleeding 호전되는 것을 확인하였음.

Imp)  
R/O ischemic colitis  
R/O CMV colitis

## 3. Gross examination, small tissue > gross text & heading

# Reporting template, SNUH

Check-list electronic file >  
Excel-based

Text join  
Copy & paste

Text report :  
semi-structured text

| A  | B                                   | C      | D    | E  | F | G         |
|----|-------------------------------------|--------|------|----|---|-----------|
| 2  | Kidney biopsy                       |        |      |    |   | Descripti |
| 3  | Microscopic findings                | :      |      |    |   | Microscop |
| 4  |                                     |        |      |    |   |           |
| 5  | Acute lesion scoring:               |        |      |    |   | Acute les |
| 6  | - Tubulitis:                        | absent | (t   | 0) |   | - Tubuli  |
| 7  | - Intimal arteritis:                | absent | (v   | 0) |   | - Intima  |
| 8  | - Interstitial inflammation:        | absent | (i   | 0) |   | - Interst |
| 9  | - Allograft glomerulitis:           | absent | (g   | 0) |   | - Allogr  |
| 10 |                                     |        |      |    |   |           |
| 11 | Chronic lesion scoring:             |        |      |    |   | Chronic l |
| 12 | - Interstitial fibrosis:            | absent | (ci  | 0) |   | - Interst |
| 13 | - Tubular atrophy:                  | absent | (ct  | 0) |   | - Tubula  |
| 14 | - Allograft glomerulopathy:         | absent | (cg  | 0) |   | - Allogr  |
| 15 | - Mesangial matrix increase:        | absent | (mm  | 0) |   | - Mesan   |
| 16 | - Vascular fibrointimal thickening: | absent | (cv  | 0) |   | - Vascul  |
| 17 | - Arteriolar hyaline thickening:    | absent | (ah  | 0) |   | - Arteric |
| 18 |                                     |        |      |    |   |           |
| 19 | Peritubular capillaritis:           | absent | (ptc | 0) |   | Peritubul |
| 20 |                                     |        |      |    |   |           |
| 21 | Glomerulus                          |        |      |    |   | Glomeru   |
| 22 | Number of Glomeruli:                |        |      |    |   |           |
| 23 | Global sclerosis:                   |        | (    | %) |   |           |
| 24 | Ischemic collapse:                  |        | (    | %) |   |           |
| 25 | Segmental sclerosis:                |        | (    | %) |   |           |
| 26 | Crescent:                           |        | (    | %) |   |           |
| 27 | (cellular:                          |        | ,    |    |   |           |
| 28 | fibrocellular:                      |        | ,    |    |   |           |
| 29 | fibrous:                            |        | )    |    |   |           |
| 30 | Loop necrosis:                      |        | (    | %) |   |           |

## Microscopic findings:

### Acute lesion scoring:

- Tubulitis: mild (t1)
- Intimal arteritis: absent (v0)
- Interstitial inflammation: mild (i1)
- Allograft glomerulitis: mild (g1)

### Chronic lesion scoring:

- Interstitial fibrosis: mild (ci1)
- Tubular atrophy: mild (ct1)
- Allograft glomerulopathy: absent (cg0)
- Mesangial matrix increase: absent (mm0)
- Vascular fibrointimal thickening: mild (cv1)
- Arteriolar hyaline thickening: mild (ah1)

Peritubular capillaritis: mild (ptc1)

### Glomerulus

- Number of Glomeruli: 24
- Global sclerosis: 8 (33.3%)
- Glomerular size: mildly increased
- Cellularity: normal
- Other findings: focal ischemic wrinkling,

Other findings: absent


### DIAGNOSIS:

- Kidney, allograft, post-transplantation 6 years, needle biopsy:
1. Borderline change (Suspicious for acute T-cell-mediated rejection)
  2. Interstitial fibrosis and tubular atrophy, grade I  
(t1, v0, i1, g1 / ci1, ct1, cg0, mm0, cv1, ah1 / ptc1)




# Pathology PACS: virtual slide

1. Previous slide review
2. Conference
3. Image analysis
4. Tumor marking
5. Research
6. Permanent storage



# Change of pathology workflow



*2nd step : digitalization of glass slides for diagnosis, not for repository*

# Digital pathology project: SNUH, 2017-2018



Digital Gross Photography system



Sequencer PCR



FISH/IF/EM images



Slide scanner x2

EMR system, 2016





Order  
Patient information  
Paper-less pathology report  
Lab work-flow management  
Slide tracking system

Pathology image server  
(HUPAX, 2009년 개발, SNUH&Humintec)  
*HP ProLiant DL380p (Gen8)*  
*Storage: 55Tb (18Tb, backup)*

Server/storage

2 servers  
55Tb >> 220Tb



HUPAX upgrade & open to whole hospital

HUPAX web viewer

Pathologist workstation (2 sets)



# Scanning




- **Objects**  
post-diagnostic : selected glasser for conference, key slides for molecular test  
*pre-diagnosis : image analysis, hepatobiliarypancreas, urology, medical kidney, bone and soft tissue, skin, CNS, pediatric cases*
- **Scan volume : File/data : 288,055 glass slides / 73Tb, 40% /total slides, 2018**
- **Scan protocol and quality**  
cover slide mounting -> drying for 20min -> loading one rack (40 slides /rack)  
Rescan rates  
    >5% [SNUH 6.3% -> 2%]  
    **stripe, focusing out**  
    histotechnical procedure : tissue fold, air bubbles, dirt on slides  
    cannot find out tissue on autofocusing : limited tissue / too little, no positive stain  
**automatic file loading to server by barcode system : no additional manual work for file management**  
**Slides can be seen within 1-3hr after loading**



# Pathology workstation



- *VS monitor : 4096x2160 resolution medical imaging display*
- *HIS monitor*
- *Secondary monitor for ancillary images  
4096x2160 resolution medical imaging display  
HUPAX web viewer*
- *3D mouse : navigation of vs*
- *PC : Intel i7-7700k, GTX1080, 8G RAM*



# Primary diagnosis by WSI, SNUH



# Diagnostic performance : SNUH

- Consecutive 235 건

| 장기             | biopsy | operation | total |
|----------------|--------|-----------|-------|
| AOV            | 2      |           | 2     |
| bile duct      | 6      | 1         | 7     |
| bone           | 2      | 4         | 6     |
| colon          | 74     |           | 74    |
| duodenum       | 3      |           | 3     |
| gallbladder    |        | 2         | 2     |
| general        |        | 5         | 5     |
| H&N            | 1      |           | 1     |
| liver          | 13     | 7         | 20    |
| LN             | 1      |           | 1     |
| lung           |        | 2         | 2     |
| medical kidney | 12     |           | 12    |
| ovary          |        | 2         | 2     |
| pancreas       | 8      | 9         | 17    |
| placenta       | 1      | 1         | 2     |
| soft tissue    | 2      | 10        | 12    |
| stomach        | 64     | 1         | 65    |
| uterus ovary   |        | 2         | 2     |
| 총합계            | 189    | 46        | 235   |

- x20 / x40(medical kidney)
- Concordant rate : 91%

- Discordant rates : 9 % (20/235)

|                     |   |
|---------------------|---|
| Activity            | 8 |
| Dysplasia grade     | 1 |
| H. pylori           | 8 |
| H. pylori, Activity | 3 |


- active inflammation : neutrophil
- dysplasia grade : low grade > high grade
- Helicobacter pylori : x20 > x400
- No missed case : malignancy, reactive atypia

# Outline


- Introduction of digital pathology
- Digital pathology for primary diagnosis
  - Component of digital pathology system for primary diagnosis
  - Digital pathology workflow, SNUH
  - Issues in implementation of digital pathology system
- **Digital pathology for research**
  - Computational pathology : quantification, discrimination, prediction
  - Reconstruction
- **New technique for digital pathology**
  - Slide-free non-destructive pathology




# Quantification (I) : Biomarker



Nuclear staining, Ki-67



Membrane staining, Her-2





Cytoplasmic staining, Hep-par1

Usage : biomarker evaluation eg. Hormone receptor, HER2, proliferation index, PD-L1

Limitation:

- automatic tumor cell identification among various cells
- Artifact : tissue, staining
- ➔ Need manual correction



Segmentation by QuPath (free software)  
Manual removal of nontumor cells or artifact  
→ 4.24% 75/1770, Neuroendocrine tumor, G2 : **tumor grading**

# Quantification (II): multiplex IHC

E.C. Stack et al. / *Methods* 70 (2014) 46–58

*Methods* 70 (2014) 46–58



Contents lists available at [ScienceDirect](http://ScienceDirect.com)



Methods

journal homepage: [www.elsevier.com/locate/ymeth](http://www.elsevier.com/locate/ymeth)

Multiplexed immunohistochemistry, imaging, and quantitation:  
A review, with an assessment of Tyramide signal amplification,  
multispectral imaging and multiplex analysis

Edward C. Stack, Chichung Wang, Kristin A. Roman, Clifford C. Hoyt\*

*PerkinElmer, Inc., Waltham, MA 02451, USA*




ER / PR / Her2 / Ki67

# Quantification (II): multiplex IHC

multiplex IHC in CRC patients

▪ Brief process of multiplex IHC method



Remark et al., Sci. Immunol. (2016) 1. aaf6925

Novel technique for evaluation of cancer immunity

▪ Brief process of multiplex IHC method


❖ Stacking of multiple virtual slide image

❖ Gain each marker's intensity value for all annotated cells

| Single | Double comb. | Triple comb.     |
|--------|--------------|------------------|
| PD-L1  | PD-L1/PD-1   | PD-L1/PD-1/CD3   |
| PD-1   | PD-1/LAG-3   | PD-1/PD-1/CD4    |
| LAG-3  | PD-L1/CD3    | PD-L1/PD-1/CD8   |
| CD3    | PD-L1/CD4    | PD-L1/PD-1/FOXP3 |


Analysis of 15,000 cells x 57 cases

Red=FOXP3  
Green=PD-1  
Blue=PD-L1



❖ PD-L1

❖ CD4/PD-1/PD-L1+ and FOXP3/PD-1/PD-L1+ TIL shows different prognostic implication




Courtesy by YJ Kwak, Department of pathology, Seoul National university Hospital presented in the 7-th annual fall meeting of the Korean society of pathologists

# Discrimination (I) : quantitative image feature

Research Article

## Quantitative nucleic features are effective for discrimination of intraductal proliferative lesions of the breast

Masatoshi Yamada<sup>1</sup>, Akira Saito<sup>2</sup>, Yoichiro Yamamoto<sup>3</sup>, Eric Cosatto<sup>4</sup>, Atsushi Kurata<sup>1</sup>, Toshitaka Nagao<sup>5</sup>, Ayako Tateishi<sup>6</sup>, Masahiko Kuroda<sup>1</sup>



**Figure 2:** Example of nuclear contour extraction results. The enlarged partial position is on the upper right. Red lines indicate the automatically extracted nuclear contour line. Yellow dots indicate the nuclear center position. The lower image is a manually created masked image. Nuclear features were measured only on selected nuclei indicated in green areas

**Table 2: Nuclear morphological parameters**

| Nucleus size and shape parameters   |                             |                         |                  |
|-------------------------------------|-----------------------------|-------------------------|------------------|
| Nucleus area size                   | Nucleus contour line length | Roundness               | Long axis length |
| Short axis length                   | Ellipsoidal ratio           | Contour line complexity | IDG1 area size   |
| Nucleus density in tissue           | Nuclear arrayment level     |                         |                  |
| Intranuclear texture parameters     |                             |                         |                  |
| GLCM angular 2 <sup>nd</sup> moment | GLCM contrast               | GLCM homogeneity        | GLCM entropy     |
| IDG2 nucleus volume                 | IDG3-8                      | IDG9-14                 | IDG15-20         |
| IDG7                                | IDG10                       | IDG11                   | IDG12            |
| IDG13                               | IDG14                       | IDG15                   | IDG16            |
| IDG21-26                            | Nuclear texture complex     |                         |                  |

Average; variance; standard deviation; median, mode; 10%, 30%, 50% 70%, and 90% tile data; 80% based average variance, standard deviation, median, mode. GLCM: Gray level co-occurrence matrix, IDG: Integrated diffusion gradient, IDG1: Ratio of nucleus area size and rectangle box area (long × short axis), IDG2: Ratio of nucleus 3D volume to cuboid volume, IDG3-8: Total volume over 6 threshold intensity levels, IDG9-14: Increased volume over each threshold intensity level, IDG15-20: Counts for each threshold intensity level cluster, IDG 21-26: Image fractal dimensions for each threshold intensity level

**Table 4b: Accuracy table**

|         | Normal | UDH (%) | ADH (%) | LG-DCIS (%) | IM-DCIS (%) | HG-DCIS (%) |
|---------|--------|---------|---------|-------------|-------------|-------------|
| Normal  |        | 97.3    | 84.8    | 93.0        | 97.9        | 97.6        |
| UDH     |        |         | 87.2    | 90.1        | 97.8        | 99.3        |
| ADH     |        |         |         | 88.1        | 94.7        | 96.7        |
| LG-DCIS |        |         |         |             | 81.8        | 97.0        |
| IM-DCIS |        |         |         |             |             | 96.0        |
| HG-DCIS |        |         |         |             |             |             |

UDH: Usual ductal hyperplasia, ADH: Atypical ductal hyperplasia, LG-DCIS: Low-grade ductal carcinoma *in situ*, IM-DCIS: Intermediate-grade ductal carcinoma *in situ*, HG-DCIS: High-grade ductal carcinoma *in situ*

# Discrimination (I) : quantitative image feature

- Discrimination by digitalized image feature >
  - Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image feature. Nat commun. 2016;7:12474

- Extract quantitative image feature : 790 items

|   |
|---|
| AreaShape_Zernike_8_6.0.5.1                                 |
| AreaShape_Zernike_8_6.0.6.1                                 |
| Texture_DifferenceEntropy_MaskedHWWithoutOverlap_3_90.0.7.1 |
| Texture_DifferenceEntropy_MaskedHWWithoutOverlap_3_45.0.8.1 |
| Texture_DifferenceEntropy_MaskedHWWithoutOverlap_3_90.0.8.1 |
| Texture_Contrast_MaskedHWWithoutOverlap_3_90.0.9.1          |
| Texture_InfoMeas2_MaskedHWWithoutOverlap_3_90.0.1.2         |
| Texture_SumVariance_MaskedHWWithoutOverlap_3_45.0.3.2       |
| AreaShape_Zernike_6_0.0.4.2                                 |

- ***Quantitative image features cannot be understood or perceived by pathologist***




Figure 3 | Quantitative image features predicted the survival outcomes of stage I lung adenocarcinoma patients. (a) Kaplan-Meier curves of lung

# Discrimination (II) : Deep learning

## Detecting Cancer Metastases on Gigapixel Pathology Images

Yun Liu<sup>1\*</sup>, Krishna Gadepalli<sup>1</sup>, Mohammad Norouzi<sup>1</sup>, George E. Dahl<sup>1</sup>,


Timo Kohlberger<sup>1</sup>, Aleksey Efros<sup>1,2</sup>, Philipp Krahenbuehl<sup>1,2</sup>

Aleksei Timofeev<sup>2</sup>, Philip Q. Nguyen<sup>1</sup>,



Lily Peng<sup>1</sup>, and

{liuyun, mnorouzi, gdahl,

<sup>1</sup>Google Brain, <sup>2</sup>Google Mountain View



Left: Images from two lymph node biopsies. Middle: earlier results of our deep learning tumor detection. Right: our current results. Notice the visibly reduced noise (potential false positives) between the two versions.



A closeup of a lymph node biopsy. The tissue contains a breast cancer metastasis as well as macrophages, which look similar to tumor but are benign normal tissue. Our algorithm successfully identifies the tumor region (bright green) and is not confused by the macrophages.

- More sensitive than pathologist, but some false positive result
- Lack of other disease pattern
- ***Assisting pathologist, not primary role***



# Find new prognostic groups

## Predicting cancer outcomes from histology and genomics using convolutional networks



Pooya Mobadersany<sup>a</sup>, Safoora Yousefi<sup>a</sup>, Mohamed Amgad<sup>a</sup>, David A. Gutman<sup>b</sup>, Jill S. Barnholtz-Sloan<sup>c</sup>, José E. Velázquez Vega<sup>d</sup>, Daniel J. Brat<sup>e</sup>, and Lee A. D. Cooper<sup>a,f,g,1</sup>

<sup>a</sup>Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA 30322; <sup>b</sup>Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322; <sup>c</sup>Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106; <sup>d</sup>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322; <sup>e</sup>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611; <sup>f</sup>Winship Cancer Institute, Emory University, Atlanta, GA 30322; and <sup>g</sup>Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30322



Edited by Bert Vogelstein, Johns Hopkins University, Baltimore, MD, and approved February 13, 2018 (received for review October 4, 2017)





TCGA-DB-5273 (IDH-mut astrocytoma)



TCGA-S9-A7J0 (IDH-mut astrocytoma)



TCGA-TM-A84G (Oligodendroglioma)





# Outline

- **Introduction of digital pathology**
- **Digital pathology for primary diagnosis**
  - Component of digital pathology system for primary diagnosis
  - Digital pathology workflow, SNUH
  - Issues in implementation of digital pathology system
- **Digital pathology for research**
  - Computational pathology : quantification, discrimination, prediction
  - Reconstruction
- **New technique for digital pathology**
  - Slide-free non-destructive pathology

# Slide-free non-destructive pathology

nature  
biomedical engineering


ARTICLES

PUBLISHED: 26 JUNE 2017 | VOLUME: 1 | ARTICLE NUMBER: 0084




## Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens



Adam K. Glaser<sup>1†</sup>, Nicholas P. Reder<sup>2†</sup>, Ye Chen<sup>1</sup>, Erin F. McCarty<sup>2</sup>, Chengbo Yin<sup>1</sup>, Linpeng Wei<sup>1</sup>, Yu Wang<sup>1</sup>, Lawrence D. True<sup>2</sup> and Jonathan T.C. Liu<sup>1\*</sup>

For the 1.7 million patients per year in the US who receive a new cancer diagnosis, treatment decisions are largely based on histopathological specimen examinations. Unfortunately, the gold standard of slide-based microscopic pathology suffers from



**Figure 1 | Open-top light-sheet microscope for clinical pathology.** **a**, An illumination light sheet enters the bottom surface of a tissue sample at an oblique 45° angle (purple). The specimen is placed on a modular glass-plate sample holder, which is inserted into a two-axis translation stage and scanned in a





# Closing

- Virtual slide : replaceable system of light microscopy: practical problems remained
- Numerous research algorithms vs few clinical use: standization of images
- Future of digital pathology

To save pathologist's time

: find tumor, mitosis, micro-organism

→ quantification, measurement, reporting

To help pathologist's decision

: segmentation and classification of cell and tissue

→ support diagnosis, grading, pattern recognition

To find new histologic feature or subtype

: survival, genetic information